A Phase 1 Open-Label Fixed-Sequence Two-Period Crossover Study Of The Effect Of Multiple Doses Of Tamoxifen On PD-0332991 Pharmacokinetics In Healthy Male Volunteers

Trial Profile

A Phase 1 Open-Label Fixed-Sequence Two-Period Crossover Study Of The Effect Of Multiple Doses Of Tamoxifen On PD-0332991 Pharmacokinetics In Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2014

At a glance

  • Drugs Palbociclib (Primary) ; Tamoxifen (Primary)
  • Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Multiple myeloma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
    • 13 Aug 2013 Planned End Date changed from 1 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top